Drug Discovery World

JULY 11, 2023

Tim Lowery , President, JSR Life Sciences, asks whether artificial intelligence can do for life sciences what it has done in other sectors and whether these tools can keep up with the complexities of human biology. So, where do we go from here to realise their potential in life sciences?

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

FEBRUARY 6, 2024

Verge Genomics’ potential amyotrophic lateral sclerosis (ALS) treatment VRG50635 is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform 6. “For By making lab automation as easy as using a smartphone, the Flex robot democratises access to automation in life sciences research.”

Marketing 69

Marketing Medicine Genome Genomics 69

pharmaphorum

APRIL 8, 2022

Her research area is the secondary use of observational data of patients with rare and unclear diseases; with attention to the research data infrastructure and terminologies. In 2021, she co-founded OHDSI Germany, which is as a national node of the Observational Health Data Sciences and Informatics (OHDSI) Europe. .

Genome 78

Genome Genomics Research Big Data 78

pharmaphorum

JULY 4, 2022

And this is where modern technologies and data-driven medical informatics can really bridge the gaps in rare disease research,” said Dr Joanne Hackett, head of Genomic and Precision Medicine at IQVIA, during a recent pharmaphorum webinar.

Genome 105

Genome Genomics Research Medicine 105

pharmaphorum

SEPTEMBER 18, 2020

German and Swiss pharma companies dominated the Swedish market at this time and it wasn’t until 1913 that the discussions were turned into a pharmaceutical company, Astra AB. Astra introduced two important product families onto the Swedish market in 1948: penicillin and anaesthetics, initially in the form of Xylocaine.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

Drug Discovery World

SEPTEMBER 6, 2022

Indeed, the growth of the cell and gene therapy market, coupled with the demand that the pandemic placed on manufacturing capacity, means the industry faces shortages of these crucial materials. The challenge for the market then, according to Boissel, is how much can a payor afford to pay upfront? .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52